Neupro Approved for Advanced Parkinson's and Restless Leg Syndrome

Thought to stimulate brain receptors governing movement

TUESDAY, April 3 (HealthDay News) -- The Neupro (rotigotine) transdermal system has been approved by the U.S. Food and Drug Administration to treat advanced Parkinson's disease and moderate-to-severe restless leg syndrome, the Belgian drug maker UCB said Tuesday in a news release.

The continuous drug delivery patch was first approved by the FDA in 2007 to treat early-stage Parkinson's.

The dopamine agonist skin patch is believed to work by stimulating dopamine receptors within the caudate-putamen, the portion of the brain that regulates movement, the company said.

In clinical testing, observed side effects of Neupro included nausea, vomiting, skin site reactions, dizziness, insomnia, and headache.

Neupro contains sodium metabisulfite, which could cause deadly allergic-like reactions in certain susceptible people. Also, the drug should not be used by pregnant women, UCB warned.

More information

To learn more about this medication, visit Medline Plus.

Copyright © 2012 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles

Meeting the Needs of Family Members of ICU Patients
Critical Care Nursing Quarterly, October/December 2014
Free access will expire on December 22, 2014.


Dealing with the specter of phantom limb pain
Nursing2014 , November 2014
Free access will expire on December 8, 2014.


The Power of Nursing Peer Review
JONA: Journal of Nursing Administration, November 2014
Free access will expire on December 8, 2014.


More Recommended Articles

Subscribe to Recommended Articles

Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events